Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYSLTR1 | Q9Y271 | 15/20 | 0.64 |
| ▸ | GRM2 | Q14416 | 12/20 | 0.64 |
| ▸ | CYSLTR2 | Q9NS75 | 4/20 | 0.49 |
| ▸ | PPARG | P37231 | 2/20 | 0.46 |
| ▸ | PPARD | Q03181 | 2/20 | 0.46 |
| ▸ | PPARA | Q07869 | 2/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | BLM | P54132 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3157572 | 0.89 | CYSLTR1 (0.63) | CYSLTR1GRM2CYSLTR2PPARGPPARD | |
| SCHEMBL8270600 | 0.87 | CYSLTR1 (0.66) | CYSLTR1GRM2CYSLTR2PPARGPPARD | |
| SCHEMBL3164665 | 0.85 | CYSLTR1 (0.68) | CYSLTR1GRM2CYSLTR2PPARGPPARD | |
| SCHEMBL3166922 | 0.85 | CYSLTR1 (0.51) | CYSLTR1GRM2CYSLTR2PPARGPPARD | |
| SCHEMBL3166919 | 0.85 | CYSLTR1 (0.62) | CYSLTR1GRM2CYSLTR2PPARGPPARD | |
| SCHEMBL13452515 | 0.84 | CYSLTR1 (0.66) | CYSLTR1GRM2CYSLTR2PPARGPPARD | |
| SCHEMBL3172081 | 0.83 | CYSLTR1 (0.76) | CYSLTR1GRM2CYSLTR2PPARGPPARD | |
| SCHEMBL3163657 | 0.83 | CYSLTR1 (0.68) | CYSLTR1GRM2CYSLTR2PPARGPPARD | |
| SCHEMBL10751332 | 0.82 | CYSLTR1 (0.58) | CYSLTR1GRM2CYSLTR2PPARGPPARD | |
| SCHEMBL3177635 | 0.81 | CYSLTR1 (0.67) | CYSLTR1GRM2CYSLTR2PPARGPPARD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1817300-B1 | POTENTIATORS OF GLUTAMATE RECEPTORS | LILLY CO ELI (US) | 2010-03-17 | — | — | EP | claimed |
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | claimed |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | ARRAY BIOPHARMA, INC. | 2008-04-24 | — | — | US | claimed |
| EP-1773774-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | claimed |
| WO-2006014918-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | claimed |
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | MERCK SHARP & DOHME CORP. | 2008-11-27 | — | — | US | disclosed |
| EP-1773774-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Merck & Co., Inc. (US) | 2007-04-18 | — | — | EP | disclosed |
| WO-2006014918-A2 | HETEROCYCLIC ACETOPHENONE POTENTIATORS OF METABOTROPIC GLUTAMATE RECEPTORS | MERCK & CO., INC. (US) | 2006-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293684-A1 | Heterocyclic Acetophenone Potentiators of Metabotropic Glutamate Receptors | GRM2, GRM1, GRIK2 | CYSLTR1 303/4885GRM2 1/4885CYSLTR2 220/4885 |
| US-20080096930-A1 | 1-(2-hydroxy-3-methyl-4-{4-[4-(1H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-phenyl)-ethanone; 6-(3-((4-acetyl-3-hydroxy-2-propylphenoxy)methyl)phenylthio)isonicotinic acid; 1-(2-hydroxy-4-{3-[4-(2H-tetrazol-5-yl)-pyridin-2-yloxy]-benzyloxy}-3-trifluoromethyl-phenyl)-ethanone; treatment of migriane | HTR7, UGT2B7, HK1 | CYSLTR1 260/4885GRM2 406/4885CYSLTR2 133/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.